ES2067508T3 - Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso. - Google Patents

Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso.

Info

Publication number
ES2067508T3
ES2067508T3 ES89115300T ES89115300T ES2067508T3 ES 2067508 T3 ES2067508 T3 ES 2067508T3 ES 89115300 T ES89115300 T ES 89115300T ES 89115300 T ES89115300 T ES 89115300T ES 2067508 T3 ES2067508 T3 ES 2067508T3
Authority
ES
Spain
Prior art keywords
analogs
radiation
dihydroisokinolinones
enhancers
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89115300T
Other languages
English (en)
Inventor
Mark James Suto
William Richard Turner
Leslie Morton Werbel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2067508T3 publication Critical patent/ES2067508T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION SELECCIONA, NUEVOS, Y CONOCIDOS ANALOGOS A ISOQUINOLINONAS DE LA FORMULA Y SALES FARMACEUTICAMENTE ACEPTABLES DE ELLOS; NUEVAS COMPOSICIONES FARMACEUTICAS; Y UN METODO PARA MEJORAR LOS EFECTOS LETALES PARA CELULAS TUMORALES A TRATAR, TENIENDO DAÑADA LA ACTIVIDAD DEL DNA, TALES COMO IONIZAR POR RADIACION O CON AGENTES QUIMIOTERAPEUTICOS.
ES89115300T 1988-08-19 1989-08-18 Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso. Expired - Lifetime ES2067508T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23470488A 1988-08-19 1988-08-19
US37275189A 1989-07-03 1989-07-03

Publications (1)

Publication Number Publication Date
ES2067508T3 true ES2067508T3 (es) 1995-04-01

Family

ID=26928219

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89115300T Expired - Lifetime ES2067508T3 (es) 1988-08-19 1989-08-18 Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso.

Country Status (7)

Country Link
EP (1) EP0355750B1 (es)
JP (1) JP2786896B2 (es)
AT (1) ATE117553T1 (es)
CA (1) CA1334969C (es)
DE (1) DE68920798T2 (es)
ES (1) ES2067508T3 (es)
GR (1) GR3015850T3 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2599992A (en) * 1991-11-12 1993-06-15 Pfizer Inc. Triazine derivatives for enhancing antitumor activity
US5391554A (en) * 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6514983B1 (en) * 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
KR100804564B1 (ko) * 2000-10-30 2008-02-20 쿠도스 파마슈티칼스 리미티드 프탈라지논 유도체
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2002090334A1 (en) * 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
US7196085B2 (en) * 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
KR20050030636A (ko) * 2002-07-24 2005-03-30 교린 세이야꾸 가부시키 가이샤 4-(치환된 아릴)-5-하이드록시이소퀴놀리논 유도체
KR100735781B1 (ko) 2002-10-01 2007-07-06 미쯔비시 웰 파마 가부시키가이샤 이소퀴놀린 화합물 및 그의 의약 용도
ES2376166T3 (es) 2002-11-22 2012-03-09 Mitsubishi Tanabe Pharma Corporation Compuestos de isoquinolina y su uso medicinal.
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
EP1651658B2 (en) 2003-08-01 2020-08-12 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant transporter
DE102004028973A1 (de) * 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
CN101801371B (zh) 2007-09-10 2012-11-28 詹森药业有限公司 可用作sglt抑制剂的化合物的制备方法
RU2010108008A (ru) 2007-09-14 2011-10-20 Астразенека Аб (Se) Фталазиноновые производные
US8183369B2 (en) 2007-10-17 2012-05-22 Kudos Pharmaceuticals Limited 4- [3- (4-cyclopropanecarbonyl-piperazine-I-carbonyl) -4 -fluoro-benzyl] -2H-phthalaz in-1-one
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
CN102482250B (zh) 2009-07-10 2014-11-19 詹森药业有限公司 1-(β-D-吡喃葡糖基)-4-甲基-3-[5-(4-氟苯基)-2-噻吩基甲基]苯的结晶方法
PL2488515T3 (pl) 2009-10-14 2017-07-31 Janssen Pharmaceutica Nv Sposób wytwarzania związków użytecznych jako inhibitory sglt2
MY187718A (en) 2010-05-11 2021-10-14 Janssen Pharmaceutica Nv Pharmaceutical formulations
WO2012140120A1 (en) 2011-04-13 2012-10-18 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB721286A (en) * 1951-02-16 1955-01-05 Smith Kline & French Internat Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives
FR2028672A6 (es) * 1968-03-06 1970-10-16 Rhone Poulenc Sa
US3674791A (en) * 1968-03-26 1972-07-04 Marion Laboratories Inc Benzamido 2 lower alkyl decahydroisoquinolines
DE2143745A1 (de) * 1971-09-01 1973-03-08 Hoechst Ag 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung
YU34792B (en) * 1972-07-18 1980-03-15 Pliva Pharm & Chem Works Process for preparing phthalazone
AR205004A1 (es) * 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona

Also Published As

Publication number Publication date
ATE117553T1 (de) 1995-02-15
EP0355750A1 (en) 1990-02-28
DE68920798D1 (de) 1995-03-09
CA1334969C (en) 1995-03-28
JPH02124874A (ja) 1990-05-14
EP0355750B1 (en) 1995-01-25
GR3015850T3 (en) 1995-07-31
DE68920798T2 (de) 1995-05-18
JP2786896B2 (ja) 1998-08-13

Similar Documents

Publication Publication Date Title
ES2067508T3 (es) Dihidroisoquinolinonas sustituidas y compuestos relacionados como potenciadores de los efectos letales de la radiacion y de ciertos agentes quimioterapeuticos; compuestos seleccionados, analogos y proceso.
PT89111A (pt) Processo de preparacao de analogos de camptotecina hidrossoluveis, dos seus intermediarios e de composicoes que os contem
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
ES502656A0 (es) Un procedimiento para la preparacion de nuevos derivados de 2-propanol
ATE143598T1 (de) Arzneimittellösung enhaltend derivate von fk506
FR2695387B1 (fr) Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
DE3681690D1 (de) N-substituierte 3-piperidin- oder 3-pyridincarbonsaeuren und deren derivate.
PT87277A (pt) Process for the preparation of new bicyclic compounds and pharmaceutical compositions comprising same
ES2068216T3 (es) Compuestos de tienotriazolodiazepina y usos farmaceuticos de los mismos.
DE68917772T2 (de) 2-Alkyl-3-benzoylbenzofurane und diese enthaltende pharmazeutische Zusammensetzungen.
DK521685D0 (da) Spergualin-derivater og anvendelse deraf til fremstilling af laegemidler med immunosuppressiv virkning
PT75602B (fr) Procede de preparation de nouvelles triazoloquinazolones et de leurs sels
NO905254D0 (no) Fremgangsmaate for fremstilling av substituerte cykloheksener.
DE69019404T2 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
ATE74138T1 (de) Heptanoyl-glu-asp-ala-amino-saeureimmunstimulanten.
FR2597097B1 (fr) Derives de benzothiazepine-1, 5, leur preparation et leur application en therapeutique
ATE19632T1 (de) Guanin-derivate.
DE3375784D1 (en) 1,3,4,6,7,11b-hexahydro-7-aryl-2h-pyrazino (2,1-alpha) isoquinolines useful as intermediates and pharmaceutical compounds and methods of preparation
ES543802A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo n-carbamiloxi sustituido
DE3880304D1 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
NO167982C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive penemderivater.
NO168580C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive beta-methylen-furanethanaminer
KR910004621A (ko) 신규 화합물
EA199800575A1 (ru) Производные пиперазина

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 355750

Country of ref document: ES